Nierofu en es it fr

Categoria

Nierofu Nombres de marca, Nierofu Analogos

Nierofu Marca los nombres de mezcla

  • No information avaliable
  • Nierofu Formula quimica

    C8H6N4O5

    Nierofu RX enlace

    http://www.rxlist.com/cgi/generic/nitro25m.htm

    Nierofu FDA hoja

    Nierofu MSDS (hoja de seguridad de materiales)

    Nierofu MSDS

    Nierofu Sintesis de referencia

    No hay información disponible

    Nierofu Peso molecular

    238.157 g/mol

    Nierofu Punto de fusion

    263 oC

    Nierofu H2O Solubilidad

    79.5 mg / L

    Nierofu Estado

    Solid

    Nierofu LogP

    -0.04

    Nierofu Formas de dosificacion

    Tableta

    Nierofu Indicacion

    Para el tratamiento de la infección del tracto urinario

    Nierofu Farmacologia

    Nitrofurantoína, un agente antibacteriano nitrofuranos, está disponible en forma microcristalina y macrocristalinas para tratar las infecciones del tracto urinario causada por muchas bacterias gram-negativas y algunas bacterias gram-positivas.

    Nierofu Absorcion

    No hay información disponible

    Nierofu Toxicidad

    No hay información disponible

    Nierofu Informacion de Pacientes

    Patients should be advised to take Macrobid with food (ideally breakfast and dinner) to further enhance tolerance and improve drug absorption. Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms occur during therapy.

    Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking Macrobid.

    Patients should be counseled that antibacterial drugs including Macrobid should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Macrobid is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Macrobid or other antibacterial drugs in the future.

    Nierofu Organismos afectados

    Gram negativos y algunas bacterias gram positivas